Zafgen Inc. (NASDAQ:ZFGN) presented secondary endpoint data from the Phase III bestPWS (ZAF-311) trial evaluating subcutaneous beloranib ( ZGN-440) to treat Prader-Willi syndrome. Data were presented at the
Read the full 282 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury